GOP lawmaker pushes back on Trump drug pricing proposal

GOP lawmaker pushes back on Trump drug pricing proposal
© Greg Nash

Rep. Larry BucshonLarry Dean Bucshon Trump unveils plan to help kidney patients in push to lower health costs House Republican: Disclosing drug prices in TV ads 'doesn't help the consumer very much' GOP lawmaker has 'a lot of concerns' over coverage if ObamaCare is overturned MORE (R-Ind.) on Friday criticized a drug pricing proposal President TrumpDonald John TrumpDavid Axelrod after Ginsburg cancer treatment: Supreme Court vacancy could 'tear this country apart' EU says it will 'respond in kind' if US slaps tariffs on France Ginsburg again leaves Supreme Court with an uncertain future MORE made last month, marking some of the first public resistance to the move from congressional Republicans.

Bucshon told The Hill that Trump’s proposal to lower some drug prices in Medicare by tying them to cheaper prices in other countries is too far of a move toward “price controls.”

ADVERTISEMENT
“It's not the direction that I would take,” Bucshon, a member of the House Energy and Commerce Committee, which oversees the issue, said. “I understand that we do want to get drug prices down but I think that any proposal that would lead to government price-fixing in that space is a pathway we don't want to follow.”

Trump’s move, announced in October, went farther in the direction of price controls on drugs than what Republicans typically support. Some Democrats praised his move, but cautioned that it did not go far enough.

But many Republicans could be hesitant to publicly criticize President Trump over the move, and some support it.

House Ways and Means Committee Chairman Kevin BradyKevin Patrick BradyRepublicans' rendezvous with reality — their plan is to cut Social Security The Social Security 2100 Act is critical for millennials and small business owners House panel releases documents of presidential tax return request before Trump MORE (R-Texas) said on Tuesday that he is still “assessing” the proposal, without praising or criticizing it.

Bucshon said other GOP lawmakers have concerns, too, without naming them. “I think a lot of people have concerns about it,” he said.

The pharmaceutical industry, which has long been a powerful force in Congress, strongly opposes the proposal. Steve Ubl, the CEO of the Pharmaceutical Research and Manufacturers of America, said last month that the proposal is “imposing foreign price controls from countries with socialized health care systems that deny their citizens access and discourage innovation.”

Asked if Congress has a role in potentially overruling the proposal, Bucshon said, “I don’t know yet.”

“That's above my paygrade to think about that, but there's ongoing discussions between the administration and people on our committee at higher levels and we'll see where it goes,” he added.

House Energy and Commerce Committee Chairman Greg WaldenGregory (Greg) Paul WaldenIs there internet life after thirty? Outdated safe harbor laws have no place in trade agreements Trump officials propose easing privacy rules to improve addiction treatment MORE (R-Ore.) has not publicly commented on the specifics of the proposal, though he released a statement after it was announced praising Trump’s commitment on drug pricing in general terms.

Sen. Lamar AlexanderAndrew (Lamar) Lamar AlexanderThe Hill's Morning Report - How will Trump be received in Dayton and El Paso? McConnell faces pressure to bring Senate back for gun legislation Criminal justice reform should extend to student financial aid MORE (R-Tenn.), the chairman of the Senate’s health committee, said last month he was “encouraged” by the proposal, making him a key supporter in Congress.

Bucshon helped lead opposition to a somewhat similar Medicare drug pricing proposal from former President Obama in 2016. The Obama administration eventually dropped the proposal in the face of opposition from Congress, the drug industry, and some doctors. 

Bucshon said he had not yet had a chance to discuss his concerns that the move would harm patients' access to innovative new drugs with the administration, but that the GOP Doctors Caucus, of which he is a member, would probably meet with Secretary of Health and Human Services Alex Azar after Thanksgiving.